A photo of Benjamin Mizukawa.

Research Director, Pediatric Cancer Avatar Program

Assistant Professor, UC Department of Pediatrics

513-636-1335

513-636-3549

Board Certified

My Biography & Research

Clinical Interests

Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics.

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Leukemia

Research Divisions

Experimental Hematology and Cancer Biology, Oncology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Utah, Salt Lake City, UT, 2004.

Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 2008; Pediatric Hematology/Oncology, 2011.

My Publications

FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Sheng, Y; Yu, C; Liu, Y; Hu, C; Ma, R; Lu, X; Ji, P; Chen, J; Mizukawa, B; Huang, Y; et al. Nature Communications. 2020; 11.

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. He, X; Dou, A; Feng, S; Roman-Rivera, A; Hawkins, C; Lawley, L; Zhang, J; Wunderlich, M; Mizukawa, B; Halene, S; et al. Experimental Hematology. 2020; 86:21-27.e2.

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Hayashi, Y; Goyama, S; Liu, X; Tamura, M; Asada, S; Tanaka, Y; Fukuyama, T; Wunderlich, M; O'Brien, E; Mizukawa, B; et al. Nature Communications. 2019; 10.

Improved chemotherapy modeling with RAG-based immune deficient mice. Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. PLoS ONE. 2019; 14:e0225532-e0225532.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65:e27400-e27400.

A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells. Du, W; Liu, W; Mizukawa, B; Shang, X; Sipple, J; Wunderlich, M; Geiger, H; Davies, S; Mulloy, J; Pang, Q; et al. Leukemia. 2018; 32:2041-2046.

Cell polarity and division symmetry analyses in transformed blood cells. Mizukawa, B; O'Brien, E; Mulloy, JC; Zheng, Y. Methods in molecular biology (Clifton, N.J.). 2018; 1821:257-266.

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Giulino-Roth, L; O'Donohue, T; Chen, Z; Bartlett, NL; LaCasce, A; Martin-Doyle, W; Barth, MJ; Davies, K; Blum, KA; Christian, B; et al. British Journal of Haematology. 2017; 179:739-747.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Mizukawa, B; O'Brien, E; Moreira, DC; Wunderlich, M; Hochstetler, CL; Duan, X; Liu, W; Orr, E; Grimes, HL; Mulloy, JC; et al. Blood. 2017; 130:1336-1346.

Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Goyama, S; Shrestha, M; Schibler, J; Rosenfeldt, L; Miller, W; O'Brien, E; Mizukawa, B; Kitamura, T; Palumbo, JS; Mulloy, JC. Oncogene: Including Oncogene Reviews. 2017; 36:2589-2598.